Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Search
  1. OncologyPRO
  2. Meeting resources
  3. ESMO Virtual Congress 2020

AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer

Panel discussion

Date

22 Sep 2020

Session

AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer

Presenters

Ignace Vergote

Authors

A. Oaknin1, I.L. Ray-Coquard2, T. Herzog3, I.B. Vergote4

Author affiliations

  • 1 Medical Oncology Dept., Vall d`Hebron University Hospital Institut d'Oncologia, 8035 - Barcelona/ES
  • 2 Medical Oncology Department, Centre Léon Bérard, 69008 - Lyon/FR
  • 3 Gynecologic Oncology, University of Cincinnati Cancer Institute, University of Cincinnati Medical Center, 45219 - Cincinnati/US
  • 4 Department Of Gynecology, University Hospitals Leuven - Campus Gasthuisberg, 3000 - Leuven/BE
More

Resources

Login to access the resources on OncologyPRO.

Login

Resources from the same session

Chair’s welcome and introductions

Presenter: Ana Oaknin

Session: AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer

Resources:

Webcast

Summary and meeting close

Presenter: Ana Oaknin

Session: AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings